Henry Mark Kuerer

Q: What Schools Are Affiliated With Henry Mark Kuerer

Henry Mark Kuerer is affiliated with the following schools: Université libre de Bruxelles, MD Anderson Cancer Center, University of Michigan, Baylor College of Medicine

Henry Mark Kuerer's AcademicInfluence.com Rankings

Henry Mark Kuerer

Philosophy

#6561

World Rank

#9617

Historical Rank

Logic

#3710

World Rank

#4908

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Henry Mark Kuerer Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Henry Mark Kuerer's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. (1999) (1301)
Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. (2007) (1171)
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. (2013) (1069)
Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. (2016) (537)
Circulating tumour cells in non-metastatic breast cancer: a prospective study. (2012) (467)
Meta‐analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer (2006) (386)
Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. (2005) (383)
Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. (2005) (369)
Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. (1999) (348)
Improved peak detection and quantification of mass spectrometry data acquired from surface‐enhanced laser desorption and ionization by denoising spectra with the undecimated discrete wavelet transform (2005) (346)
Role of ultrasound‐guided fine‐needle aspiration of indeterminate and suspicious axillary lymph nodes in the initial staging of breast carcinoma (2002) (345)
Breast cancer on the world wide web: cross sectional survey of quality of information and popularity of websites (2002) (327)
RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. (2015) (318)
Delayed-Immediate Breast Reconstruction (2004) (314)
Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero (2006) (311)
Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. (2005) (295)
Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. (2004) (295)
Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. (2005) (288)
Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. (2000) (284)
Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy is Accurate and Reduces the Need for Axillary Dissection in Breast Cancer Patients (2009) (282)
Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. (2001) (281)
Image-detected breast cancer: state of the art diagnosis and treatment. (2005) (277)
Clinicopathologic Factors Predicting Involvement of Nonsentinel Axillary Nodes in Women With Breast Cancer (2003) (276)
Career Satisfaction, Practice Patterns and Burnout among Surgical Oncologists: Report on the Quality of Life of Members of the Society of Surgical Oncology (2007) (275)
Role for Intraoperative Margin Assessment in Patients Undergoing Breast-Conserving Surgery (2007) (262)
Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. (2004) (259)
Effect of Primary Tumor Extirpation in Breast Cancer Patients Who Present With Stage IV Disease and an Intact Primary Tumor (2006) (247)
Accuracy of Physical Examination, Ultrasonography, and Mammography in Predicting Residual Pathologic Tumor Size in Patients Treated With Neoadjuvant Chemotherapy (2006) (244)
Classifying local disease recurrences after breast conservation therapy based on location and histology (2002) (243)
Ductal carcinoma in situ: state of the science and roadmap to advance the field. (2009) (236)
Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial (2019) (230)
Quality control and peak finding for proteomics data collected from nipple aspirate fluid by surface-enhanced laser desorption and ionization. (2003) (229)
Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. (2007) (227)
Positive surgical margins and ipsilateral breast tumor recurrence predict disease‐specific survival after breast‐conserving therapy (2003) (205)
Small (< or = 2-cm) breast cancer treated with US-guided radiofrequency ablation: feasibility study. (2004) (204)
Long-term complications associated with breast-conservation surgery and radiotherapy (2002) (199)
Presentation, treatment, and outcome of local recurrence after skin-sparing mastectomy and immediate breast reconstruction (2006) (198)
Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2‐positive breast cancer (2010) (192)
Genomic grade index is associated with response to chemotherapy in patients with breast cancer. (2009) (186)
Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. (2002) (185)
Lipofilling of the Breast Does Not Increase the Risk of Recurrence of Breast Cancer: A Matched Controlled Study (2016) (183)
Biological Markers in DCIS and Risk of Breast Recurrence: A Systematic Review (2011) (182)
Determining the Optimal Approach to Breast Reconstruction after Partial Mastectomy (2006) (181)
Which threshold for ER positivity? a retrospective study based on 9639 patients. (2014) (171)
Trends in and Outcomes from Sentinel Lymph Node Biopsy (SLNB) Alone vs. SLNB with Axillary Lymph Node Dissection for Node-Positive Breast Cancer Patients: Experience from the SEER Database (2010) (171)
Metastases to the breast from nonbreast solid neoplasms (2007) (163)
American College of Surgeons Oncology Group (ACOSOG) Z0011: Impact on Surgeon Practice Patterns (2012) (162)
Feasibility and Accuracy of Sentinel Lymph Node Biopsy After Preoperative Chemotherapy in Breast Cancer Patients With Documented Axillary Metastases (2007) (161)
Three‐year analysis of treatment efficacy, cosmesis, and toxicity by the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial in patients treated with accelerated partial breast irradiation (APBI) (2008) (160)
The Role for Sentinel Lymph Node Dissection after Neoadjuvant Chemotherapy in Patients who Present with Node-Positive Breast Cancer (2012) (159)
Five-year analysis of treatment efficacy and cosmesis by the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial in patients treated with accelerated partial breast irradiation. (2011) (158)
Consensus Guidelines on Genetic` Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons (2019) (157)
MRI Phenotype Is Associated With Response to Doxorubicin and Cyclophosphamide Neoadjuvant Chemotherapy in Stage III Breast Cancer (2001) (155)
The Safety of Lymphatic Mapping in Pregnant Breast Cancer Patients Using Tc‐99m Sulfur Colloid (2004) (152)
A Standard Set of Value-Based Patient-Centered Outcomes for Breast Cancer: The International Consortium for Health Outcomes Measurement (ICHOM) Initiative (2017) (149)
Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response (2004) (149)
Breast conservation after neoadjuvant chemotherapy (2005) (149)
First analysis of patient demographics, technical reproducibility, cosmesis, and early toxicity (2005) (149)
Surgical decision making and factors determining a diagnosis of breast carcinoma in women presenting with nipple discharge. (2003) (148)
Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. (1998) (148)
Treatment and outcome of patients with intracystic papillary carcinoma of the breast. (2002) (145)
Validation of a Breast Cancer Nomogram for Predicting Nonsentinel Lymph Node Metastases After a Positive Sentinel Node Biopsy (2006) (144)
Factors Affecting the Decision of Breast Cancer Patients to Undergo Contralateral Prophylactic Mastectomy (2010) (144)
Impact of Preoperative Versus Postoperative Chemotherapy on the Extent and Number of Surgical Procedures in Patients Treated in Randomized Clinical Trials for Breast Cancer (2006) (144)
Practical Guidelines for Repair of Partial Mastectomy Defects Using the Breast Reduction Technique in Patients Undergoing Breast Conservation Therapy (2007) (141)
Selective surgical localization of axillary lymph nodes containing metastases in patients with breast cancer: a prospective feasibility trial. (2015) (140)
The molecular journey from ductal carcinoma in situ to invasive breast cancer (2008) (139)
Proteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein (2006) (136)
Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery (2017) (133)
Low locoregional failure rates in selected breast cancer patients with tumor‐positive sentinel lymph nodes who do not undergo completion axillary dissection (2007) (132)
Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. (2010) (132)
The effect of ethnicity on immediate reconstruction rates after mastectomy for breast cancer (2004) (130)
Intraoperative margin assessment reduces reexcision rates in patients with ductal carcinoma in situ treated with breast-conserving surgery. (2003) (128)
Identification and Evaluation of Axillary Sentinel Lymph Nodes in Patients With Breast Carcinoma Treated With Neoadjuvant Chemotherapy (2000) (127)
Society of Surgical Oncology: Position Statement on Prophylactic Mastectomy. Approved by the Society of Surgical Oncology Executive Council, March 2007 (2007) (126)
Feasibility of Immediate Breast Reconstruction for Locally Advanced Breast Cancer (1999) (125)
Impact of Clinicopathological Factors on Sensitivity of Axillary Ultrasonography in the Detection of Axillary Nodal Metastases in Patients With Breast Cancer (2003) (125)
A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy (2017) (124)
A Management Algorithm and Practical Oncoplastic Surgical Techniques for Repairing Partial Mastectomy Defects (2008) (123)
Incorporation of Sentinel Lymph Node Metastasis Size Into a Nomogram Predicting Nonsentinel Lymph Node Involvement in Breast Cancer Patients With a Positive Sentinel Lymph Node (2012) (122)
Multidisciplinary Considerations in the Implementation of the Findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 Study: A Practice-Changing Trial (2011) (122)
Operative and Oncologic Outcomes in 9861 Patients with Operable Breast Cancer: Single-Institution Analysis of Breast Conservation with Oncoplastic Reconstruction (2016) (120)
Ipsilateral breast tumor recurrence after breast conservation therapy: outcomes of salvage mastectomy vs. salvage breast-conserving surgery and prognostic factors for salvage breast preservation. (2005) (119)
Mammography before diagnosis among women age 80 years and older with breast cancer. (2008) (118)
Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. (2005) (118)
Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance). (2015) (117)
Locoregional recurrence risk for patients with T1,2 breast cancer with 1-3 positive lymph nodes treated with mastectomy and systemic treatment. (2014) (117)
Predictors of locoregional recurrence among patients with early-stage breast cancer treated with breast-conserving therapy (2007) (116)
Feasibility of Breast Preservation in the Treatment of Occult Primary Carcinoma Presenting With Axillary Metastases (2001) (115)
Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma (2004) (114)
Prospective Evaluation of the Nipple–Areola Complex Sparing Mastectomy for Risk Reduction and for Early-Stage Breast Cancer (2012) (113)
Conservative surgery and chemotherapy for breast carcinoma during pregnancy. (2002) (111)
Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry (2004) (109)
Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. (2012) (106)
Improving local control with breast‐conserving therapy (2005) (105)
Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. (2012) (105)
Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials (2016) (104)
Predicting the Extent of Nodal Disease in Early-Stage Breast Cancer (2014) (102)
Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. (2005) (102)
A prospective study comparing touch imprint cytology, frozen section analysis, and rapid cytokeratin immunostain for intraoperative evaluation of axillary sentinel lymph nodes in breast cancer (2009) (101)
Timing of Surgical Intervention for the Intact Primary in Stage IV Breast Cancer Patients (2008) (101)
Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline‐based neoadjuvant chemotherapy in patients with breast carcinoma (2002) (101)
Higher parity and shorter breastfeeding duration (2010) (100)
Accelerated Partial Breast Irradiation After Conservative Surgery for Breast Cancer (2004) (100)
Multidisciplinary management of breast cancer concurrent with pregnancy. (2002) (98)
The Nuclear Transcription Factor κB/bcl-2 Pathway Correlates with Pathologic Complete Response to Doxorubicin-Based Neoadjuvant Chemotherapy in Human Breast Cancer (2005) (97)
Global Gene Expression Changes During Neoadjuvant Chemotherapy for Human Breast Cancer (2002) (97)
Incidence of anaphylactoid reactions to isosulfan blue dye during breast carcinoma lymphatic mapping in patients treated with preoperative prophylaxis (2005) (94)
Advances and surgical decision‐making for breast reconstruction (2006) (92)
Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system. (2011) (92)
Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. (2002) (92)
Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy. (2016) (91)
Accuracy of the Combination of Mammography and Sonography in Predicting Tumor Response in Breast Cancer Patients After Neoadjuvant Chemotherapy (2006) (91)
Incidence and Prevention of Venous Thromboembolism in Patients Undergoing Breast Cancer Surgery and Treated According to Clinical Pathways (2006) (90)
Breast Reconstruction in Older Women: Advantages of Autogenous Tissue (2003) (89)
A prospective trial of preoperative chemotherapy in resectable breast cancer: Predictors of breast-conservation therapy feasibility (2002) (89)
Impact of Chemotherapy Sequencing on Local-Regional Failure Risk in Breast Cancer Patients Undergoing Breast-Conserving Therapy (2013) (88)
Long-term outcomes in patients with mucinous, medullary, tubular, and invasive ductal carcinomas after lumpectomy. (2007) (87)
Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy (2016) (87)
Disparities in the Use of Breast-Conserving Therapy Among Patients With Early-Stage Breast Cancer. (2015) (85)
Contralateral prophylactic mastectomy (2004) (85)
Comparative analysis of sentinel lymph node operation in male and female breast cancer patients. (2006) (84)
Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy (2018) (82)
Intramammary lymph node metastases are an independent predictor of poor outcome in patients with breast carcinoma (2004) (80)
Identification of Biomarkers for Breast Cancer in Nipple Aspiration and Ductal Lavage Fluid (2005) (80)
Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges. (2020) (79)
Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status. (1998) (78)
Radiofrequency ablation of early-stage invasive breast tumors: an overview. (2002) (77)
Advances in breast conservation therapy. (2005) (77)
Selective use of sentinel lymph node surgery during prophylactic mastectomy (2006) (77)
Impact of Surgical Techniques, Biomaterials, and Patient Variables on Rate of Nipple Necrosis after Nipple-Sparing Mastectomy (2013) (76)
How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer? (2008) (76)
Prospective randomized trial of paravertebral block for patients undergoing breast cancer surgery. (2009) (75)
Biology, Treatment, and Outcome in Very Young and Older Women with DCIS (2012) (75)
Multidisciplinary considerations in the management of high-risk breast lesions. (2012) (74)
Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. (2007) (74)
Paget’s Disease of the Breast: There Is a Role for Breast-Conserving Therapy (2005) (74)
Role of primary tumor characteristics in predicting positive sentinel lymph nodes in patients with ductal carcinoma in situ or microinvasive breast cancer. (2008) (74)
Present-Day Locoregional Control in Patients with T1 or T2 Breast Cancer with 0 and 1 to 3 Positive Lymph Nodes After Mastectomy Without Radiotherapy (2010) (74)
Local, regional, and systemic recurrence rates in patients undergoing skin‐sparing mastectomy compared with conventional mastectomy (2011) (72)
Current treatment and clinical trial developments for ductal carcinoma in situ of the breast. (2007) (72)
Chest Wall Recurrence After Mastectomy Does Not Always Portend a Dismal Outcome (2003) (72)
Clinical outcome of patients with lymph node‐negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry (2005) (72)
Descriptions and outcomes of insertion techniques of a breast brachytherapy balloon catheter in 1403 patients enrolled in the American Society of Breast Surgeons MammoSite breast brachytherapy registry trial. (2005) (71)
Multimodality Imaging for Evaluating Response to Neoadjuvant Chemotherapy in Breast Cancer. (2017) (70)
T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy. (2004) (68)
Burnout and Career Satisfaction Among Surgical Oncologists Compared with Other Surgical Specialties (2010) (67)
Four-year clinical update from the American Society of Breast Surgeons MammoSite brachytherapy trial. (2009) (67)
A phase I study to assess the feasibility and oncologic safety of axillary reverse mapping in breast cancer patients (2010) (66)
Case control study of women treated with chemotherapy for breast cancer during pregnancy as compared with nonpregnant patients with breast cancer. (2013) (66)
The effect of under-treatment of breast cancer in women 80 years of age and older. (2011) (65)
Primary Tumor Extirpation in Breast Cancer Patients Who Present with Stage IV Disease is Associated with Improved Survival (2013) (64)
Correlation between HER‐2 expression and response to neoadjuvant chemotherapy with 5‐fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma (2003) (64)
Outcomes of breast-conservation therapy for invasive lobular carcinoma are equivalent to those for invasive ductal carcinoma. (2006) (63)
Impact of the american college of surgeons oncology group Z0011 criteria applied to a contemporary patient population. (2013) (63)
Initial Outcomes for Patients Treated on the American Society of Breast Surgeons MammoSite Clinical Trial for Ductal Carcinoma-In-Situ of the Breast (2006) (62)
A Multidisciplinary Protocol for Planned Skin-Preserving Delayed Breast Reconstruction for Patients with Locally Advanced Breast Cancer Requiring Postmastectomy Radiation Therapy: 3-Year Follow-Up (2011) (62)
Locoregional treatment outcomes for inoperable anthracycline-resistant breast cancer. (2002) (61)
Is Sentinel Lymph Node Dissection Warranted for Patients with a Diagnosis of Ductal Carcinoma In Situ? (2015) (61)
Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer (2006) (60)
Prospective Study of Surgical Decision-making Processes for Contralateral Prophylactic Mastectomy in Women With Breast Cancer. (2016) (60)
Neoadjuvant chemotherapy in women with invasive breast carcinoma: conceptual basis and fundamental surgical issues. (2000) (60)
Preliminary results and evaluation of MammoSite balloon brachytherapy for partial breast irradiation for pure ductal carcinoma in situ: a phase II clinical study. (2006) (60)
Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast (2011) (59)
Anaphylaxis during breast cancer lymphatic mapping. (2001) (59)
Six-Year Analysis of Treatment-Related Toxicities in Patients Treated with Accelerated Partial Breast Irradiation on the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial (2012) (58)
Evaluation of Lymph Node Status in Male Breast Cancer Patients: A Role for Sentinel Lymph Node Biopsy* (2004) (58)
Breast conservation therapy as a treatment option for the elderly (2001) (58)
Nomograms for Predicting Axillary Response to Neoadjuvant Chemotherapy in Clinically Node-Positive Patients with Breast Cancer (2016) (56)
Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast cancer (2014) (56)
Nonoperative Management for Invasive Breast Cancer After Neoadjuvant Systemic Therapy: Conceptual Basis and Fundamental International Feasibility Clinical Trials (2017) (56)
Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy (2009) (56)
Update on DCIS Outcomes from the American Society of Breast Surgeons Accelerated Partial Breast Irradiation Registry Trial (2010) (55)
Implementation of the American College of Surgeons Oncology Group Z1071 Trial Data in Clinical Practice: Is There a Way Forward for Sentinel Lymph Node Dissection in Clinically Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy? (2014) (54)
Evaluation of the MD Anderson Prognostic Index for Local-Regional Recurrence After Breast Conserving Therapy in Patients Receiving Neoadjuvant Chemotherapy (2012) (54)
Repeat breast‐conserving surgery for in‐breast local breast carcinoma recurrence (2004) (54)
Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. (2008) (52)
The safety of breast‐conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy (2006) (51)
Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin‐based neoadjuvant chemotherapy (2005) (51)
Classification of Ipsilateral Breast Tumor Recurrences After Breast Conservation Therapy Can Predict Patient Prognosis and Facilitate Treatment Planning (2011) (51)
Use of Sentinel Lymph Node Dissection After Neoadjuvant Chemotherapy in Patients with Node-Positive Breast Cancer at Diagnosis: Practice Patterns of American Society of Breast Surgeons Members (2017) (50)
Sentinel lymph node surgery in locally recurrent breast cancer. (2006) (50)
Identification of distinct protein expression patterns in bilateral matched pair breast ductal fluid specimens from women with unilateral invasive breast carcinoma (2002) (50)
Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ (2004) (49)
Clinical studies of vaccines targeting breast cancer. (2003) (49)
Histologic changes associated with false‐negative sentinel lymph nodes after preoperative chemotherapy in patients with confirmed lymph node‐positive breast cancer before treatment (2010) (49)
Wound complications from surgery in pregnancy-associated breast cancer (PABC). (2010) (49)
Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer (2013) (48)
Lymphatic Drainage Patterns on Early Versus Delayed Breast Lymphoscintigraphy Performed after Injection of Filtered Tc-99m Sulfur Colloid in Breast Cancer Patients Undergoing Sentinel Lymph Node Biopsy (2005) (48)
Utility of Breast Sentinel Lymph Node Biopsy Using Day-Before-Surgery Injection of High-Dose 99mTc-Labeled Sulfur Colloid (2001) (48)
Implications of Axillary Sentinel Lymph Node Biopsy in Immediate Autologous Breast Reconstruction (2002) (47)
Nipple aspirate fluid cytology in breast carcinoma (2002) (47)
Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy (2012) (47)
Predictors of systemic recurrence and disease‐specific survival after ipsilateral breast tumor recurrence (2005) (46)
Ductal Carcinoma-In-Situ of the Breast with Subsequent Distant Metastasis and Death (2011) (46)
Effective Local Control and Long-Term Survival in Patients with T4 Locally Advanced Breast Cancer Treated with Breast Conservation Therapy (2004) (46)
Drains Prevent Seromas Following Lumpectomy with Axillary Dissection (2000) (46)
Lymphatic mapping and sentinel lymph node biopsy for breast cancer: developments and resolving controversies. (2005) (46)
Factors Associated With Lymphedema in Women With Node-Positive Breast Cancer Treated With Neoadjuvant Chemotherapy and Axillary Dissection. (2019) (46)
Anaphylactoid reactions to isosulfan blue dye during breast cancer lymphatic mapping in patients given preoperative prophylaxis. (2004) (45)
Ductal lavage and the clinical management of women at high risk for breast carcinoma (2002) (45)
Breast carcinoma associated with pregnancy and lactation. (1997) (45)
Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer (1998) (44)
Incidence and Consequence of Close Margins in Patients with Ductal Carcinoma-In Situ Treated with Mastectomy: Is Further Therapy Warranted? (2013) (44)
A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding. (2005) (44)
Use of lymphoscintigraphy defines lymphatic drainage patterns before sentinel lymph node biopsy for breast cancer. (2006) (44)
Impact of randomized clinical trial results in the national comprehensive cancer network on the use of tamoxifen after breast surgery for ductal carcinoma in situ. (2007) (44)
Feasibility of confocal fluorescence microscopy for real-time evaluation of neoplasia in fresh human breast tissue (2013) (44)
Immediate breast reconstruction after skin-sparing mastectomy for the treatment of advanced breast cancer: Radiation oncology considerations (2002) (43)
Breast ductal secretions: clinical features, potential uses, and possible applications. (2007) (43)
Racial disparities in adoption of axillary sentinel lymph node biopsy and lymphedema risk in women with breast cancer. (2014) (43)
Lymphovascular Invasion and Lobular Histology are Associated with Increased Incidence of Isolated Tumor Cells in Sentinel Lymph Nodes from Early-Stage Breast Cancer Patients (2008) (42)
Abstract GS4-04: Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer (2019) (42)
Circulating Tumor Cells After Neoadjuvant Chemotherapy in Stage I–III Triple-Negative Breast Cancer (2015) (41)
DCIS Margins and Breast Conservation: MD Anderson Cancer Center Multidisciplinary Practice Guidelines and Outcomes (2017) (41)
Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline‐ and nonanthracycline‐based regimens for HER2‐positive breast cancer (2012) (41)
Improved Postoperative Pain Control using Thoracic Paravertebral Block for Breast Operations (2009) (41)
Impact of Progression During Neoadjuvant Chemotherapy on Surgical Management of Breast Cancer (2011) (40)
Ductal Carcinoma-In-Situ: Long-Term Results of Breast-Conserving Therapy (2000) (40)
NRG Oncology-Radiation Therapy Oncology Group Study 1014: 1-Year Toxicity Report From a Phase 2 Study of Repeat Breast-Preserving Surgery and 3-Dimensional Conformal Partial-Breast Reirradiation for In-Breast Recurrence. (2017) (40)
Effectiveness of Breast-Conserving Surgery and 3-Dimensional Conformal Partial Breast Reirradiation for Recurrence of Breast Cancer in the Ipsilateral Breast: The NRG Oncology/RTOG 1014 Phase 2 Clinical Trial. (2019) (39)
Accuracy of Post-Neoadjuvant Chemotherapy Image-Guided Breast Biopsy to Predict Residual Cancer. (2020) (39)
Microcalcifications in 1657 Patients with Pure Ductal Carcinoma in Situ of the Breast: Correlation with Clinical, Histopathologic, Biologic Features, and Local Recurrence (2016) (39)
Potential applicability of balloon catheter–based accelerated partial breast irradiation after conservative surgery for breast carcinoma (2004) (39)
A report on accrual rates for elderly and minority-ethnicity cancer patients to clinical trials of the American College of Surgeons Oncology Group. (2004) (39)
High Prevalence of Preinvasive Lesions Adjacent to BRCA1/2-Associated Breast Cancers (2009) (37)
Delays in Primary Surgical Treatment Are Not Associated With Significant Tumor Size Progression in Breast Cancer Patients (2011) (37)
Biopsy Feasibility Trial for Breast Cancer Pathologic Complete Response Detection after Neoadjuvant Chemotherapy: Imaging Assessment and Correlation Endpoints (2018) (37)
Comment on ‘Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques' (2016) (37)
Association between ductal fluid proteomic expression profiles and the presence of lymph node metastases in women with breast cancer. (2004) (36)
Outcomes of Sentinel Lymph Node-Positive Breast Cancer Patients Treated with Mastectomy Without Axillary Therapy (2017) (36)
2–35 Partial Breast Irradiation in Breast-Conserving Therapy by Way of Interstitial Brachytherapy (2005) (36)
Patient-Reported Outcomes for Breast Cancer (2018) (36)
Management of axillary disease. (2014) (36)
Innate immune function after breast, lung, and colorectal cancer surgery. (2015) (35)
Lower and central tumor location correlates with lymphoscintigraphy drainage to the internal mammary lymph nodes in breast carcinoma (2005) (35)
Histologic Localization of Sentinel Lymph Node Metastases in Breast Cancer (2003) (34)
High and differential expression of HER-2/neu extracellular domain in bilateral ductal fluids from women with unilateral invasive breast cancer. (2003) (34)
Performance and Practice Guideline for the Use of Neoadjuvant Systemic Therapy in the Management of Breast Cancer (2015) (33)
Timing of Chemotherapy after MammoSite radiation therapy system breast brachytherapy: analysis of the American Society of Breast Surgeons MammoSite breast brachytherapy registry trial. (2008) (33)
Comparison of Ductal Lavage and Random Periareolar Fine Needle Aspiration as Tissue Acquisition Methods in Early Breast Cancer Prevention Trials (2007) (33)
Treatment and outcome of patients with chest wall recurrence after mastectomy and breast reconstruction. (2004) (32)
Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy. (2004) (32)
Limited evidence of human papillomavirus on breast tissue using molecular in situ methods (2012) (32)
Prognostic Value of Circulating Tumor Cells Identified Before Surgical Resection in Nonmetastatic Breast Cancer Patients. (2016) (32)
Circulating Tumor Cells and Recurrence After Primary Systemic Therapy in Stage III Inflammatory Breast Cancer. (2015) (32)
Value-Based Breast Cancer Care: A Multidisciplinary Approach for Defining Patient-Centered Outcomes (2016) (32)
The biologic rationale for and emerging role of accelerated partial breast irradiation for breast cancer. (2004) (32)
Radiologic Mapping for Targeted Axillary Dissection: Needle Biopsy to Excision. (2016) (31)
Current National Health Insurance Coverage Policies for Breast and Ovarian Cancer Prophylactic Surgery (2000) (31)
Local Recurrence and Survival Among Black Women With Early-Stage Breast Cancer Treated With Breast-Conservation Therapy or Mastectomy (1999) (31)
Does Blue Dye Contribute to Success of Sentinel Node Mapping for Breast Cancer? (2010) (30)
Local control, toxicity, and cosmesis in women >70 years enrolled in the American Society of Breast Surgeons accelerated partial breast irradiation registry trial. (2012) (30)
Factors predictive of having four or more positive axillary lymph nodes in patients with positive sentinel lymph nodes: implications for selection of radiation fields. (2004) (30)
Specimen radiography in confirmation of MRI-guided needle localization and surgical excision of breast lesions. (2006) (30)
Circulating tumor cells in non-metastatic triple-negative breast cancer (2014) (29)
Ductal carcinoma in situ treated with breast‐conserving surgery and accelerated partial breast irradiation (2011) (29)
Adverse events associated with the intraoperative injection of isosulfan blue. (2004) (29)
Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox. (2021) (28)
DCIS and axillary nodal evaluation: compliance with national guidelines (2017) (28)
Clinicopathologic, mammographic, and sonographic features in 1,187 patients with pure ductal carcinoma in situ of the breast by estrogen receptor status (2013) (27)
Identification of breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment by an intelligent vacuum-assisted biopsy. (2020) (27)
American Society of Breast Surgeons MammoSite Radiation Therapy System Registry Trial: ductal carcinoma-in-situ subset analysis--4-year data in 194 treated lesions. (2009) (27)
Failure to Harvest Sentinel Lymph Nodes Identified by Preoperative Lymphoscintigraphy in Breast Cancer Patients (2003) (27)
Collective reviewProphylactic mastectomy (2000) (27)
Thirty-Gene Pharmacogenomic Test Correlates with Residual Cancer Burden after Preoperative Chemotherapy for Breast Cancer (2007) (26)
Disseminated tumor cells predict survival after neoadjuvant therapy in primary breast cancer (2012) (26)
Tumor Bed Control with Balloon-Based Accelerated Partial Breast Irradiation: Incidence of True Recurrences Versus Elsewhere Failures in the American Society of Breast Surgery MammoSite® Registry Trial (2012) (26)
Outcome of treatment for breast cancer patients with chest wall recurrence according to initial stage: implications for post-mastectomy radiation therapy. (2003) (26)
Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory Breast Cancer (2017) (26)
Kuerer's Breast Surgical Oncology (2010) (26)
Ductal Carcinoma In Situ and Margins <2 mm: Contemporary Outcomes With Breast Conservation (2017) (26)
Local Control, Toxicity, and Cosmesis in Women Younger Than 50 Enrolled Onto the American Society of Breast Surgeons MammoSite Radiation Therapy System Registry Trial (2009) (26)
Impact of concurrent proliferative high‐risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast‐conserving therapy (2006) (25)
The rationale for integration of lymphatic mapping and sentinel node biopsy in the management of breast cancer after neoadjuvant chemotherapy (2002) (25)
Improved Locoregional Control in a Contemporary Cohort of Nonmetastatic Inflammatory Breast Cancer Patients Undergoing Surgery (2017) (25)
Impact of race and ethnicity on features and outcome of ductal carcinoma in situ of the breast (2013) (25)
Breast cancer metastasis through the lympho-vascular system (2018) (25)
Novel Clinical Trial Designs for Treatment of Ductal Carcinoma In Situ of the Breast with Trastuzumab (Herceptin) (2007) (25)
Feasibility of breast‐conserving surgery for patients with breast carcinoma associated with nipple discharge (2004) (24)
Road map for maintaining career satisfaction and balance in surgical oncology. (2008) (23)
Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer (2018) (23)
Ductal carcinoma in situ: treatment or active surveillance? (2015) (23)
Features Associated with Successful Recruitment of Diverse Patients onto Cancer Clinical Trials: Report from the American College of Surgeons Oncology Group (2011) (23)
Homing receptors and addressins. (1991) (23)
Decision analysis to assess the efficacy of routine sentinel lymphadenectomy in patients undergoing prophylactic mastectomy (2007) (23)
Axillary lymph node cellular immune response to HER-2/neu peptides in patients with carcinoma of the breast. (2002) (23)
Molecular detection of micrometastatic breast cancer in histopathology-negative axillary lymph nodes correlates with traditional predictors of prognosis: An interim analysis of a prospective multi-institutional cohort study (2005) (23)
Clinical Utility of the 12-Gene DCIS Score Assay: Impact on Radiotherapy Recommendations for Patients with Ductal Carcinoma In Situ (2016) (22)
Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ (2012) (22)
Factors impacting the accuracy of intra‐operative evaluation of sentinel lymph nodes in breast cancer (2018) (22)
Ductal Carcinoma In Situ: Treatment Update and Current Trends (2015) (21)
Is partial breast irradiation a step forward or backward? (2005) (21)
Expanding Implementation of ACOSOG Z0011 in Surgeon Practice (2018) (21)
Digital Breast Tomosynthesis for Intraoperative Margin Assessment during Breast-Conserving Surgery (2019) (21)
Residual specimen cellularity after neoadjuvant chemotherapy for breast cancer (2007) (20)
Other Primary Malignancies in Breast Cancer Patients Treated with Breast Conserving Surgery and Radiation Therapy (2013) (20)
Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. (2011) (20)
Biologic basis and evolving role of aromatase inhibitors in the management of invasive carcinoma of the breast (2001) (20)
Targeting and limiting surgery for patients with node-positive breast cancer (2015) (20)
Breast cancer in the very elderly: treatment patterns and complications in a tertiary cancer center. (2006) (19)
The effect of undertreatment of breast cancer in women 80 years of age and older (2011) (19)
Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology/RTOG 9804 (2021) (19)
Imaging-Based Approach to Axillary Lymph Node Staging and Sentinel Lymph Node Biopsy in Patients With Breast Cancer. (2019) (19)
Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations (2018) (19)
Disseminated Tumor Cells in Biologic Subtypes of Stage I–III Breast Cancer Patients (2010) (18)
Clinical Course of Breast Cancer Patients with Isolated Sternal and Full-Thickness Chest Wall Recurrences Treated With and Without Radical Surgery (2013) (18)
Impact of Sentinel Lymph Node Biopsy on the Evolution of Breast Reconstruction (2006) (18)
Neoadjuvant Radiotherapy to Facilitate Immediate Breast Reconstruction: A Systematic Review and Current Clinical Trials (2019) (18)
NRG Oncology/RTOG 1014: 3 Year Efficacy Report From a Phase II Study of Repeat Breast Preserving Surgery and 3D Conformal Partial Breast Re-Irradiation (PBrI) for In-Breast Recurrence (2015) (17)
Surgeon perception versus reality: Opioid use after breast cancer surgery (2019) (17)
Correlation between sonographic findings and clinicopathologic and biologic features of pure ductal carcinoma in situ in 691 patients. (2015) (17)
Unusual aspects of breast cancer: case 3. Blue hives during lymphatic mapping for breast cancer. (2001) (17)
Patient Selection for Clinical Trials Eliminating Surgery for HER2-Positive Breast Cancer Treated with Neoadjuvant Systemic Therapy (2019) (17)
Performance of Mid-Treatment Breast Ultrasound and Axillary Ultrasound in Predicting Response to Neoadjuvant Chemotherapy by Breast Cancer Subtype. (2017) (17)
Predictors that Influence Contralateral Prophylactic Mastectomy Election Among Women with Ductal Carcinoma In Situ Who Were Evaluated for BRCA Genetic Testing (2014) (16)
Breast-conservation therapy in early-stage breast cancer patients with a positive family history (2002) (16)
Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial. (2022) (16)
Should oncoplastic breast conserving surgery be used for the treatment of early stage breast cancer? Using the GRADE approach for development of clinical recommendations (2021) (16)
Epstein–Barr virus is seldom found in mammary epithelium of breast cancer tissue using in situ molecular methods (2012) (16)
Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer. (2009) (16)
Prospective Registry Trial Assessing the Use of Magnetic Seeds to Locate Clipped Nodes After Neoadjuvant Chemotherapy for Breast Cancer Patients (2021) (16)
Establishing a Program for Individuals at High Risk for Breast Cancer (2013) (16)
A 10-Year Experience with Mastectomy and Tissue Expander Placement to Facilitate Subsequent Radiation and Reconstruction (2017) (16)
Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non‐surgical management of triple‐negative breast cancer (2018) (15)
Nipple Aspirate Fluid Cytology and the Gail Model for Breast Cancer Risk Assessment in a Screening Population (2005) (15)
Optimizing Breast Cancer Adjuvant Radiation and Integration of Breast and Reconstructive Surgery. (2017) (15)
Breast conserving surgery and locoregional control after neoadjuvant chemotherapy. (2017) (15)
American Society of Breast Surgeons’ Practice Patterns After Publication of the SSO-ASTRO-ASCO DCIS Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation (2018) (15)
Outcomes of Volume Replacement Oncoplastic Breast-Conserving Surgery Using Chest Wall Perforator Flaps: Comparison with Volume Displacement Oncoplastic Surgery and Total Breast Reconstruction (2020) (15)
Proton Partial-Breast Irradiation for Early-Stage Cancer: Is It Really So Costly? (2016) (15)
Management of Local-Regional Recurrence following Immediate Breast Reconstruction in Patients with Early Breast Cancer Treated without Postmastectomy Radiotherapy (2011) (14)
Hepatic resection for breast cancer liver metastases: Impact of intrinsic subtypes. (2020) (14)
Sentinel lymph node dissection provides axillary control equal to complete axillary node dissection in breast cancer patients with lobular histology and a negative sentinel node. (2005) (14)
Outcome after ipsilateral breast tumor recurrence in patients who receive accelerated partial breast irradiation (2012) (14)
Determinants of mastectomy in breast conservation therapy candidates. (2005) (14)
Determinants of Breast Conservation Rates: Reasons for Mastectomy at a Comprehensive Cancer Center (2009) (14)
Feasibility and utility of using chromosomal aneusomy to further define the cytologic categories in nipple aspirate fluid specimens (2004) (14)
Feasibility of fine‐needle aspiration for assessing responses to chemotherapy in metastatic nodes marked with clips in breast cancer: A prospective registry study (2018) (13)
Evolution in practice patterns of axillary management following mastectomy in patients with 1–2 positive sentinel nodes (2019) (13)
Elevated Luteinizing Hormone in Serum, Breast Cancer Tissue, and Normal Breast Tissue from Breast Cancer Patients (2002) (13)
Response to Induction Chemotherapy in Black and White Patients with Locally Advanced Breast Cancer (2000) (13)
Sentinel lymph node biopsy following neoadjuvant chemotherapy: review of the literature and recommendations for use in patient management. (2004) (13)
Invasive lobular carcinoma predicts micrometastasis in breast cancer. (2012) (13)
Opioid Use after Breast-Conserving Surgery: Prospective Evaluation of Risk Factors for High Opioid Use (2019) (12)
Abstract GS5-04: Accuracy of post-neoadjuvant chemotherapy image-guided breast biopsy to predict the presence of residual cancer: A multi-institutional pooled analysis (2020) (12)
Preoperative axillary ultrasound in breast cancer: Safely avoiding frozen section of sentinel lymph nodes in breast-conserving surgery (2014) (12)
Steatocystoma multiplex: appearance at mammography. (1991) (12)
Confocal fluorescence microscopy to evaluate changes in adipocytes in the tumor microenvironment associated with invasive ductal carcinoma and ductal carcinoma in situ (2016) (12)
Prospective evaluation of a novel approach for the use of a quantitative galactose oxidase–Schiff reaction in ductal fluid samples from women with breast carcinoma (2004) (12)
Micro-anatomical quantitative optical imaging: toward automated assessment of breast tissues (2015) (12)
The Changing Paradigms for Breast Cancer Surgery: Performing Fewer and Less-Invasive Operations (2018) (12)
A prospective analysis of the effect of blue-dye volume on sentinel lymph node mapping success and incidence of allergic reaction in patients with breast cancer (2005) (12)
Low-risk Breast Ductal Carcinoma In Situ (DCIS): Results From the Radiation Therapy Oncology Group 9804 Phase 3 Trial (2012) (12)
Rational individualised selection of adjuvant therapy for ductal carcinoma in situ. (2011) (11)
Conservative Surgery for Breast Carcinoma Associated with Pregnancy (1998) (11)
Axillary Failure in Patients Treated with MammoSite Accelerated Partial Breast Irradiation (2011) (11)
Innominate Vein Stenosis Mimicking Locally Advanced Breast Cancer in a Dialysis Patient (2001) (11)
Current National Health Insurance Policies for Thyroid Cancer Prophylactic Surgery in the United States (2002) (10)
Paradigm Shifts in Breast Care Delivery: Impact of Imaging in a Multidisciplinary Environment. (2017) (10)
Breast conservation therapy after neoadjuvant chemotherapy: Optimization of a multimodality approach (2014) (10)
Improving cancer care through quality measures: putting evidence to work with the COC. (2013) (10)
Reply to 'A standard mastectomy should not be the only recommended breast surgical treatment for non-metastatic inflammatory breast cancer: A large population-based study in the Surveillance, Epidemiology, and End Results database 18'. (2018) (9)
Minimally invasive operation for breast cancer. (2004) (9)
Breast Cancer Management Updates: Young and Older, Pregnant, or Male (2015) (9)
Body mass index mediates the prognostic significance of circulating tumor cells in inflammatory breast cancer. (2017) (9)
Effectiveness and Safety of Magseed-localization for Excision of Breast Lesions: A Prospective, Phase IV Trial. (2020) (9)
A new measurement of residual cancer burden to predict survival after neoadjuvant chemotherapy. (2006) (9)
Factors Associated with Pathological Node Negativity in Inflammatory Breast Cancer: Are There Patients Who May be Candidates for a De-Escalation of Axillary Surgery? (2020) (9)
Timing of Infectious Complications Following Breast-Conserving Therapy with Catheter-Based Accelerated Partial Breast Irradiation (2014) (9)
The treatment of pregnant women with breast cancer and the outcomes of the children exposed to chemotherapy in utero (2005) (9)
Using the National Cancer Data Base for quality evaluation to assess adherence to treatment guidelines for nonmetastatic inflammatory breast cancer (2017) (9)
Pilot trial of cryoprobe-assisted breast-conserving surgery for small ultrasound-visible cancers (2004) (9)
Predictors that Influence Election of Contralateral Prophylactic Mastectomy among Women with Ductal Carcinoma in Situ who are BRCA-Negative (2015) (9)
Outcomes of Curative-Intent Treatment for Patients With Breast Cancer Presenting With Sternal or Mediastinal Involvement. (2019) (9)
Invasive cutaneous fungal infections requiring radical resection in cancer patients undergoing chemotherapy (2004) (8)
Recurrence and Survival in the American Society of Breast Surgeons (ASBS) MammoSite ® RTS Registry Trial (2008) (8)
Optimal Selection of Breast Cancer Patients for Elimination of Surgery Following Neoadjuvant Systemic Therapy. (2017) (8)
Outcomes and Predictive Factors for Salvage Therapy After Local–Regional Recurrence Following Neoadjuvant Chemotherapy and Breast Conserving Therapy (2013) (8)
Sonographic features of benign and malignant axillary nodes post‐neoadjuvant chemotherapy (2020) (8)
Bone marrow micrometastases in breast cancer. (2005) (8)
The evolving role of proteomics in the early detection of breast cancer. (2005) (8)
Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass (2012) (8)
Two year analysis of treatment efficacy and cosmesis by the American Society of Breast Surgeons (ASBS) MammoSite Breast Brachytherapy Registry Trial in patients treated with accelerated partial breast irradiation (APBI) (2006) (8)
De-escalation towards omission is the tipping point of individualizing breast cancer surgery. (2020) (7)
False Negative Rate of Sentinel Lymph Node Biopsy in Multicentric and Multifocal Breast Cancers May be Higher in Cases with Large Additive Tumor Burden (2009) (7)
Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer. (2019) (7)
Radiation treatment improves local-regional control and survival in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy (2003) (7)
Three-year Analysis of Treatment Efficacy, Cosmesis and Toxicity by the American Society of Breast Surgeons (ASBS) MammoSite® Breast Brachytherapy Registry Trial in Patients Treated With Accelerated Partial Breast Irradiation (APBI) (2007) (7)
Molecular subtyping of DCIS: Heterogeneity of breast cancer reflected in pre-invasive disease (2011) (7)
Incidence and Outcome of Breast Biopsy Procedures During Follow-up After Treatment for Breast Cancer (2018) (7)
Incremental cancer detection using breast ultrasonography versus breast magnetic resonance imaging in the evaluation of newly diagnosed breast cancer patients. (2016) (6)
The Role of Mastectomy in De Novo Stage IV Inflammatory Breast Cancer (2021) (6)
Incremental Cancer Detection of Locoregional Restaging with Diagnostic Mammography Combined with Whole-Breast and Regional Nodal Ultrasound in Women with Newly Diagnosed Breast Cancer. (2017) (6)
Evaluation of BRCAPRO Risk Assessment Model in Patients with Ductal Carcinoma In situ Who Underwent Clinical BRCA Genetic Testing (2016) (6)
Residual tumor thickness at the tumor-normal tissue interface predicts the recurrence-free survival in patients with liver metastasis of breast cancer. (2014) (6)
Integration of neoadjuvant chemotherapy and surgery in the treatment of patients with breast carcinoma. (2001) (6)
Special considerations in breast cancer risk and survival (1999) (6)
Disparities in the Use of Postmastectomy Radiation Therapy for Inflammatory Breast Cancer. (2016) (6)
Two year analysis of treatment efficacy and cosmesis by the American Society of Breast Surgeons (ASBS) MammoSite Breast Brachytherapy Registry Trial in patients treated with accelerated partial breast irradiation (APBI). (2006) (6)
Excellent Locoregional Control in Inflammatory Breast Cancer with a Personalized Radiotherapy Approach. (2019) (5)
Integrating partial breast irradiation into surgical practice and clinical trials. (2007) (5)
Use of Mammographic Measurements to Predict Complications After Nipple-Sparing Mastectomy in BRCA Mutation Carriers (2019) (5)
The 2018 Compensation Survey of the American Society of Breast Surgeons (2019) (5)
2006 : Two Year Actuarial Analysis of 198 Patients With DCIS Treated With Accelerated Partial Breast Irradiation (APBI): Efficacy, Cosmesis and Toxicity in Patients on the American Society of Breast Surgeons (ASBS) MammoSite Breast Brachytherapy Registry Trial (2006) (5)
Postive sentinel nodes after neoadjuvant chemotherapy: What factors predict additional disease in the axilla? (2006) (5)
Educational Review: Role of the Surgeon in Hereditary Breast Cancer (2001) (5)
Strain difference in galactokinase level and susceptibility to the teratogenic effect of dietary galactose in mice: I. Teratogenic and embryopathic effect. (1988) (5)
Molecular profiling using breast cancer subtype to plan for breast reconstruction. (2017) (5)
Important technical considerations for skin-sparing mastectomy with sentinel lymph node dissection. (2002) (5)
Web based pathology assessment in RTOG 98-04 (2014) (5)
Abstract P5-16-30: Feasibility trial for identification of patients for eliminating breast cancer surgery following neoadjuvant systemic therapy (2017) (4)
Impact of the early COVID‐19 pandemic on Breast Surgical Oncology fellow education (2021) (4)
Thomsen-Friedenreich and Tn Antigens in Nipple Fluid: Carbohydrate Biomarkers for Breast Cancer Detection (2006) (4)
Training of breast surgical oncologists. (2016) (4)
Erratum: Limited evidence of human papillomavirus on breast tissue using molecular in situ methods (2012) (4)
Breast Cancer in Patients With Prior Augmentation: Presentation, Stage, and Lymphatic Mapping (2005) (4)
State of the Science and the Intraductal Approach for Breast Cancer: Proceedings Summary of The Sixth International Symposium on the Intraductal Approach To Breast Cancer Santa Monica, California, 19–21 February 2009 (2009) (4)
RADIATION THERAPY ONCOLOGY GROUP RTOG 1014 A PHASE II STUDY OF REPEAT BREAST PRESERVING SURGERY AND 3D-CONFORMAL PARTIAL BREAST RE-IRRADIATION (PBRI) FOR LOCAL RECURRENCE OF BREAST CARCINOMA (2010) (4)
Sentinel Lymph Node Biopsy Performed After Neoadjuvant Chemotherapy is Accurate in Patients with Documented Node-Positive Breast Cancer at Presentation (2008) (4)
Contralateral Axillary Metastasis in Patients with Inflammatory Breast Cancer (2021) (4)
Acceptability of 3D‐printed breast models and their impact on the decisional conflict of breast cancer patients: A feasibility study (2021) (4)
Molecular Profiling Using Breast Cancer Subtype to Plan for Breast Reconstruction. (2017) (4)
Oncologic safety of breast-conserving surgery compared to mastectomy in patients receiving neoadjuvant chemotherapy for locally advanced breast cancer: Cho JH, Park JM, Park HS, et al (Yonsei Univ College of Medicine, Seoul, Republic of Korea) J Surg Oncol 108:531-536, 2013 (2014) (4)
Intraoperative radiotherapy for early breast cancer (2010) (4)
Contemporary breast conservation patient outcomes for ductal carcinoma in situ and margins < 2 mm. (2017) (4)
Optimizing Breast Cancer Adjuvant Radiation and Integration of Breast and Reconstructive Surgery. (2017) (4)
Erratum: Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ. Cancer. 2012;118:1515-22. (2014) (3)
Her2-Neu overexpression does not increase the risk of local-regional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiation (2003) (3)
Nomogram to predict sentinel lymph node involvement in patients with clinically node-negative breast cancer receiving neoadjuvant chemotherapy. (2012) (3)
Reply to K.J. Van Zee et al (2012) (3)
Anatomy and physiology of the sentinel lymph nodes of the upper extremity: Implications for axillary reverse mapping in breast cancer (2020) (3)
Use of genomic grade index (GGI) to predict pathologic response to preoperative chemotherapy in breast cancer (2008) (3)
Breast Cancer in the Asian Indian Population of the United States: A Call for Screening and Education (2008) (3)
The Role of Ultrasound in the Surgical Management of Patients Diagnosed with Ductal Carcinoma in Situ of the Breast (2006) (3)
Abstract P5-17-03: The 12-gene DCIS score assay: Impact on radiation treatment (XRT) recommendations and clinical utility (2016) (3)
Complications of Wise-Pattern Compared With Vertical Scar Mastopexy/Breast Reduction in Oncoplastic Breast-Conserving Surgery (2020) (3)
The clinical impact of proliferative high-risk lesions presenting concurrently with ductal carcinoma in situ (DCIS) in patients (pts) treated with breast conserving therapy (BCT) (2005) (3)
Stimulation of cells from a non-invaded and an invaded lymph node with a HER-2+ tumor with peptides corresponding to T-cell epitopes E75 and G89 induced expansion of central memory cells (TCM) from the metastasis-negative lymph nodes. (2004) (3)
Discordance in HER 2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer (2013) (3)
Breast Cancer Clinical Trials: Past Half Century Moving Forward Advancing Patient Outcomes (2016) (3)
Laparoscopic vs. Open Surgery for Rectal Cancer (2015) (3)
Same-Day Breast Cancer Surgery and TARGIT-IORT: Better than Selective Omission of Radiotherapy? (2021) (2)
Accelerated partial breast irradiation as an alternative to whole breast irradiation in breast-conserving therapy for early-stage breast cancer. (2005) (2)
De-escalating Surgery Among Patients with HER2 + and Triple Negative Breast Cancer (2022) (2)
ASO Visual Abstract: Contralateral Axillary Metastasis in Patients with Inflammatory Breast Cancer (2021) (2)
Impact of chemotherapy timing on local-regional failures in patients with breast cancer undergoing breast-conserving therapy. (2011) (2)
Intracavitary balloon brachytherapy for breast cancer: Surgical considerations. Authors' reply (2003) (2)
Effect of hormone receptor status and local treatment on overall survival for early-stage breast cancer. (2014) (2)
The Virtual Scientific Sessions from the American Society of Breast Surgeons During the COVID-19 Pandemic (2020) (2)
Long-term Oncologic Outcomes in Patients with Inflammatory Breast Cancer with Supraclavicular Nodal Involvement (2022) (2)
Detection of discordant HER2 status by FISH in circulating tumor cells and disseminated tumor cells in early-stage breast cancer using a microfluidic-based cell enrichment and extraction platform (OncoCEE). (2012) (2)
Breast Preservation in Patients with Local Recurrence After Breast-Conserving Therapy (2011) (2)
Predictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who tested negative for a BRCA mutation. (2014) (2)
Impact of Progression during Neoadjuvant Chemotherapy on Operative Management of Breast Cancer. (2009) (2)
NRG Oncology/RTOG 1014: Patient Reported Outcomes (PRO) and Cosmesis From a Phase II Study of Repeat Breast Preserving Surgery and 3D Conformal (3D-CRT) Partial Breast Re-Irradiation (PBrI) for In-Breast Recurrence. (2018) (2)
If at First or Second You Don’t Succeed: Mastectomy? (2005) (2)
Abstract S2-3: Disparities in the utilization of axillary sentinel lymph node biopsy among black and white patients with node-negative breast cancer from 2002–2007. (2012) (2)
Oral Scientific SessionNRG Oncology/RTOG 1014: 1-Year Toxicity Report From a Phase II Study of Repeat Breast Preserving Surgery and 3D Conformal Partial-Breast Reirradiation (PBrI) for In-Breast Recurrence (2015) (2)
Clinical Course of Breast Cancer Patients with Local-Regional Progression During Neoadjuvant Systemic Therapy (2021) (2)
Surgery for inoperable breast cancer. (2002) (2)
(P015) Radiotherapy After Skin-Sparing Mastectomy and Placement of a Tissue Expander: Effectiveness of a Coordinated, Multidisciplinary Approach (2017) (2)
Long-term outcome of patients with complete eradication of cytologically proven axillary node metastases after primary chemotherapy: The University of Texas M. D. Anderson Cancer Center experience (2004) (2)
More evidence for further minimisation of breast-cancer surgery. (2018) (2)
The health and well-being of American surgery. (2012) (2)
Sentinel lymph node dissection provides similar local-regional control compared to axillary dissection in patients with node negative breast cancer (2005) (2)
Bilateral Paget's Disease of the Male Breast (1998) (2)
Sentinel lymph node biopsy followed by delayed mastectomy and reconstruction. (2005) (1)
Radiotherapy and Tamoxifen for Ductal Carcinoma in Situ (2011) (1)
Intracavitary balloon brachytherapy for breast cancer: surgical considerations. in regard to Keisch M, Vicini F, Kuske RR, et al., IJROBP 2003;55:289-293. (2003) (1)
Implications of sentinel lymph node biopsy in the setting of immediate breast reconstruction (2004) (1)
Impact of Post-Mastectomy Radiation Therapy (PMRT) in Women with T1-2N1M0 Breast Cancer: A Multi-Institutional Analysis (2020) (1)
2018 Annual Meeting Official Proceedings, Volume XIX (2018) (1)
To Look or Not to Look? Yes to Nodal US! (2021) (1)
Tamoxifen added to radiotherapy and surgery for the treatment of ductal carcinoma in situ of the breast: A meta-analysis of 2 randomized trials: Petrelli F, Barni S (Azienda Ospedaliera Treviglio-Caravaggio, Bergamo, Italy) Radiother Oncol 100:195-199, 2011§ (2012) (1)
Intramammary lymph node metastases are an independent predictor in breast cancer outcomes (2004) (1)
FOAM CELLS IN NIPPLE ASPIRATION FLUID (2002) (1)
10-year outcomes of breast cancer patients with histologically confirmed axillary lymph node metastases and pathologic complete response after primary systemic chemotherapy. (2013) (1)
Is Axillary Dissection Necessary in Breast Cancer Patients with Positive Sentinel Lymph Nodes (2011) (1)
Accelerated Partial Breast Irradiation as an Alternative to Whole-Breast Irradiation in Breast-Conserving Therapy for Early-Stage Breast Cancer (2005) (1)
Primary tumor resection to improve survival and local disease control in stage IV inflammatory breast cancer. (2012) (1)
Con: Sentinel Lymph Node Biopsy for DCIS. The Breast Surgeon is not a Barber (2007) (1)
3-Year Follow-Up of the Partial Breast Irradiation Trial for DCIS Using the MammoSite® Brachytherapy Balloon Catheter. (2009) (1)
Sentinel lymph node biopsy accurately reflects nodal status following preoperative chemotherapy for breast cancer (2004) (1)
2019 Annual Meeting Official Proceedings, Volume XX (2019) (1)
Prognostic value of residual cancer burden after neoadjuvant taxane-anthracycline chemotherapy in phenotypic subsets of breast cancer (2008) (1)
Modulation of breast cancer cell-free DNA with surgical resection. (2013) (1)
Navigating treatment controversies for DCIS in the era of genomic profiling and active surveillance trials. (2018) (1)
(S003) Curative-Intent Treatment for Newly Diagnosed Breast Cancer With Limited Metastatic Disease to the Sternum or Mediastinum (2017) (1)
Postmastectomy Radiotherapy for Breast Cancer Patients with One to Three Positive Nodes (2014) (1)
Utility of a One-Step Nucleic Acid Amplification (OSNA) Assay for Comprehensive Examination of Axillary Lymph Nodes in Breast Cancer. (2009) (1)
In reply [15] (2005) (1)
Does Diagnostic Radiation Increase Breast Cancer Risk in Women with BRCA Mutations (2012) (1)
P4-07-11: Circulating Tumor Cells after Neoadjuvant Therapy Predict Outcome in Stage I to III Breast Cancer. (2011) (1)
Are mastectomy rates really increasing? Experiences from a single institution and a population-based database. (2012) (1)
Delayed Bilateral Pneumothorax after Subclavian Vein Catheterization (1995) (1)
Increasing Breast Cancer Systemic Therapy Use Before Surgery in the United States: Scaling Down and the Promise of Selective Elimination of Surgery (2018) (1)
MD Anderson Cancer Center Feasibility Trial for Eliminating Breast Cancer Surgery in Exceptional Responders (2016) (1)
P067: Assessment of burnout among breast surgeons in the United Kingdom (2020) (1)
Transdisciplinary studies of surgical oncology trial accrual (2006) (1)
Limiting Axillary Surgery for Patients with Initial Biopsy-Proven Axillary Metastases After Preoperative Chemotherapy: To Clip or Not to Clip? (2016) (1)
Predicting the extent of nodal disease in early breast cancer. (2013) (1)
High resolution microendoscopy with structured illumination and Lugol's iodine staining for evaluation of breast cancer architecture (2016) (1)
Career Development for Breast Surgical Oncology (2010) (1)
Chemotherapy for Isolated Locoregional Recurrence of Breast Cancer (2018) (1)
Prophylactic mastectomy in women with a high risk of breast cancer. (1999) (0)
Eliminating Breast Cancer Surgery with Neoadjuvant Chemotherapy (2015) (0)
Accelerated Partial Breast Irradiation for Early Breast Cancer (2015) (0)
DCIS of the Breast: A Look towards Discovery and Advancements in the Field (2007) (0)
EFFECTS OF ILOPROST (PGI2) ON CARDIAC TAMPONADE‐INDUCED PORCINE MESENTERIC ISCHEMIA: 11 (1995) (0)
Controversies and Clinical Trials for DCIS: Margins and Active Surveillance (2017) (0)
Survival Benefit of Breast Surgery for Low-Grade Ductal Carcinoma In Situ: A Population-Based Cohort Study (2016) (0)
2016 Annual Meeting Official Proceedings, Volume XVII (2016) (0)
Ipsilateral breast tumor recurrence (IBTR) following breast conservation therapy: Outcomes of salvage mastectomy (SM) vs. salvage breast conserving surgery (SBCS) and prognostic factors for salvage breast preservation (2004) (0)
Impact of Post-Mastectomy Radiation Therapy in Women With T1-2N1M0 Breast Cancer With Sentinel Lymph Node Biopsy Alone. (2021) (0)
Radiotherapy vs. Surgery for Breast Cancer Patients with Axillary Lymph Node Metastases (2014) (0)
Sentinel Lymph Node Biopsy Following Neoadjuvant Chemotherapy : Review of the Literature and Recommendations for Use in Patient (2009) (0)
ASO Visual Abstract: Long-Term Oncologic Outcomes in Patients with Inflammatory Breast Cancer with Supraclavicular Nodal Involvement (2022) (0)
ASO Visual Abstract: Clinical Course of Breast Cancer Patients with Local Regional Progression During Neoadjuvant Systemic Therapy (2021) (0)
ASO Author Reflections: Neoadjuvant Radiotherapy Followed by Immediate Breast Reconstruction Represents a Novel Therapeutic Sequence for Breast Cancer (2019) (0)
P4-10-06: Evaluation of BRCAPro Risk Assessment Model in Patients with Ductal Carcinoma In Situ. (2011) (0)
Commentary (2001) (0)
Lymph Node Biopsy in Older Patients with Breast Cancer (2009) (0)
Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials (2016) (0)
Proceed With Caution: Concerns Related to Routine Internal Mammary Lymph Node Radiation for Node-Positive Breast Cancer. (2016) (0)
A novel staging system for disease-specific survival in patients with breast cancer treated with surgery as the first intervention. (2011) (0)
Nipple-Sparing Mastectomy (2009) (0)
Axillary-conserving surgery is facilitated by neoadjuvant chemotherapy of breast cancer: Beatty JD, Precht LM, Lowe K, et al (Swedish Med Ctr, Seattle, WA; Fred Hutchinson Cancer Res Ctr, Seattle, WA) Am J Surg 197:637-642, 2009§ (2009) (0)
TARGIT: Targeted Intraoperative Radiotherapy with Low-Energy X-Rays for Breast Cancer (2013) (0)
2–21 Patient and Duct Selection for Nipple Duct Lavage (2005) (0)
Comparison of pathological risk factors for postmastectomy local-regional recurrence after neoadjuvant versus adjuvant chemotherapy for patients not treated with radiation (2001) (0)
Outcomes of sentinel lymph node-positive breast cancer patients treated with mastectomy without axillary therapy. (2013) (0)
Long-term outcome of patients with complete eradication of cytologically proven axillary node metastases after primary chemotherapy: The University of Texas M. D. Anderson Cancer Center experience. (2004) (0)
Will Axillary Radiotherapy Replace Axillary Dissection in Women with Positive Sentinel Nodes (2011) (0)
Sorting out the Survival Impact of Radiation Therapy in Early-Stage Invasive Breast Cancer (2014) (0)
Prediction of chemosensitivity of breast tumors treated with primary chemotherapy using clinical nomograms (2007) (0)
Are Textured Implants After Mastectomy Associated with Breast Cancer Recurrence (2020) (0)
Outcomes of Curative-Intent Treatment for Breast Cancer Patients Presenting with Sternal or Mediastinal Involvement (2017) (0)
Prognostic Value of Circulating Tumor Cells Identified prior to Surgical Resection in Non-Metastatic Breast Cancer Patients (2018) (0)
Surgical consideration for accelerated partial breast irradiation (2006) (0)
SENTINEL LYMPH NODE BIOPSY AFTER NEOADJUVANT CHEMOTHERAPY (2014) (0)
Circulating And Disseminated Tumor Cells After Neoadjuvant Therapy In Primary Breast Cancer (2011) (0)
MRI to Diagnose Pure DCIS (2007) (0)
P5-01-17: HER2 Amplification in Primary Tumor: A Potential Marker for Presence of Circulating Tumor Cells in Inflammatory Breast Cancer Patients? (2011) (0)
The role of ultrasound in the surgical management of patients diagnosed with ductal carcinoma in situ of the breast. (2006) (0)
ASO Author Reflections: Selecting Patients for Elimination of Surgery Trials—Predicting Residual Invasive and In Situ Disease in Patients with HER2-Positive Breast Cancer After Neoadjuvant Systemic Therapy (2019) (0)
22nd Annual Virtual Meeting of the American Society of Breast Surgeons: Science, Innovation, and Practice Changes (2021) (0)
CT Screening and Lung Cancer Detection in Patients at High Risk (2007) (0)
Primary Surgery for Initial Metastatic Breast Cancer (2015) (0)
Ductal Carcinoma In Situ: Clinical Trials Update and Resolving Controversies (2012) (0)
Abstract P3-01-05: Circulating tumor cell detection predicts early recurrence in patients with non-metastatic breast cancer (2019) (0)
Quantification of Adipocyte Area at Invasive Breast Tumor Margins and in Benign Stroma (2014) (0)
Breast-Implant–Associated Anaplastic Large Cell Lymphoma (2020) (0)
Abstract P6-08-06: Characteristics of ductal carcinoma in situ (DCIS) in patients who underwent multigene panel testing for hereditary breast cancer (2020) (0)
ASO Visual Abstract: Predictors of Emergency Room Visits After Ambulatory Breast Cancer Surgery in the Medicare Population (2023) (0)
American Society of Breast Surgeons MammoSite® Registry: Ductal carcinoma in-situ subset – three-year data in 194 cancers (2008) (0)
Abstract PS2-42: Identify breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment - an international, multicenter analysis (2021) (0)
Axillary Ultrasound After Preoperative Chemotherapy in Node-Positive Breast Cancer (2015) (0)
Mastectomy Is More Common in Medicaid Patients (2013) (0)
Postmastectomy Radiotherapy: Updated Guidelines (2016) (0)
Local control, toxicity and cosmesis in women younger than 50 enrolled on the american society of breast surgeons mammosite® RTS registry trial (2008) (0)
Value-Based Breast Cancer Care (2016) (0)
Laparoscopic Colectomy for Colon Cancer (2008) (0)
Radiation for Ductal Carcinoma In Situ (2006) (0)
Re-Excision After Breast-Conserving Surgery (2014) (0)
Colon Cancer Survival Linked to Number of Lymph Nodes Resected (2007) (0)
Is Axillary Dissection Necessary in Women with Early Breast Cancer and a Positive Sentinel Lymph Node (2010) (0)
Planned Radiation in Axillary Management of Breast Cancer (2017) (0)
1–35 Comprehensive Axillary Evaluation in Neoadjuvant Chemotherapy Patients With Ultrasonography and Sentinel Lymph Node Biopsy (2006) (0)
Multifocal Breast Cancer Treated with Neoadjuvant Chemotherapy (2006) (0)
Abstract PD3-07: A phase II pre-surgical trial of lapatinib for the treatment of women with HER2 positive or EGFR positive ductal carcinoma in situ (2019) (0)
Intramammary lymph node metastases are an independent predictor in breast cancer outcomes. (2004) (0)
Breast Cancer Axillary Surgery: Before, After, or None at All? (2016) (0)
Abstract PS1-17: Comparing survival differences between breast-conserving therapy and mastectomy in patients with early-stage breast cancer undergoing upfront surgery (2021) (0)
Quantitative analysis of morphology associated with progression from non-proliferative and hyperplastic ducts to ductal carcinoma in Situ in human breast tissue (2013) (0)
Axillary Lymph Node Dissection Becoming Less Common in Sentinel Lymph Node–Positive Breast Cancer (2007) (0)
Eliminating Breast Surgery for Invasive Cancer with Exceptional Response to Neoadjuvant Systemic Therapy: Prospective Multicenter Clinical Trial Planned Initial Feasibility Endpoint. (2023) (0)
Sorting Out the Complications of Brachytherapy for Breast Cancer (2013) (0)
Adverse Cosmesis with Accelerated Partial-Breast Irradiation (2013) (0)
A nomogram to predict axillary response to neoadjuvant chemotherapy in clinically node positive breast patients. (2015) (0)
Five-Gene Signature for Survival in Non–Small-Cell Lung Cancer Patients (2007) (0)
Abstract P1-07-09: Estrogen receptor positivity: 10% or 1%? (2012) (0)
Disparities in utilization of breast-conserving therapy among breast cancer patients. (2014) (0)
Benefits of Radiotherapy After Breast-Conserving Surgery (2011) (0)
3–22 Mastectomy and Concomitant Sentinel Lymph Node Biopsy for Invasive Breast Cancer (2005) (0)
Reexcision in Breast-Conserving Surgery (2012) (0)
Influence of Margin Status on Outcomes in Lobular Carcinoma: Experience of the European Institute of Oncology: Galimberti V, Maisonneuve P, Rotmensz N, et al (Univ of Milan, Italy; et al) Ann Surg 253:580-584, 2011§ (2011) (0)
Stage migration after introduction of sentinel lymph node dissection in breast cancer treatment in Denmark: A nationwide study (2012) (0)
Omitting Radiation for Patients with DCIS (2009) (0)
Predictors of Emergency Room Visits After Ambulatory Breast Cancer Surgery in the Medicare Population (2022) (0)
The Multidisciplinary Spectrum of Cancer Therapy: Effects on Immediate Breast Reconstruction (2010) (0)
Partial Breast Irradiation After Breast-Conserving Surgery (2017) (0)
Selecting Appropriate Patients with Hepatocellular Carcinoma for Liver Transplantation (2007) (0)
Surgeons’ Volume Status Doesn’t Affect Cancer-Related Mortality in Older Women with Early-Stage Breast Cancer (2007) (0)
Use of tamoxifen after surgery for ductal carcinoma in situ (2004) (0)
Proceed with Caution: MRI Evaluation in Women with New Breast Cancer (2007) (0)
Initial biopsy procedure for breast cancer diagnosis influences number of surgical procedures and cost of care. (2006) (0)
P3-07-05: Nomogram Incorporating SLN Metastasis Size Provides the Most Accurate Prediction of Non-SLN Involvement in Breast Cancer Patients. (2011) (0)
Breast-Conserving Therapy vs. Mastectomy for Triple-Negative Breast Cancer (2011) (0)
Should Sex Be a Factor in Screening Guidelines for Colorectal Cancer (2006) (0)
Sentinel L ymph N ode B iopsy I s A ccurate A fter N eoadjuvant Chemotherapy f or B reast C ancer (2000) (0)
Abstract P5-14-07: Comparison of infectious complications between breast conserving therapy with catheter-based accelerated partial irradiation and whole breast irradiation (2013) (0)
Breast Cancer Risk from Atypical Ductal Hyperplasia in the Modern Era (2016) (0)
Invasive Lobular Carcinoma Predicts Micrometastatic Disease in Stage I-III Breast Cancer (2012) (0)
Comparing Survival Differences Between Breast-Conserving Therapy and Mastectomy in Patients with Early-Stage Breast Cancer (2020) (0)
Margins for Conservative Surgery in Stage I and II Invasive Breast Cancer (2014) (0)
2-22 Patterns of Participation and Successful Patient Recruitment to American College of Surgeons Oncology Group Z0010, a Phase II Trial for Patients With Early-Stage Breast Cancer (2006) (0)
Breast-Implant–Associated Large Cell Lymphoma (2014) (0)
60 – Solitary Metastases (2018) (0)
Chronic Pain After Breast Cancer Surgery (2009) (0)
The impact of hormone receptor status on pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy with or without trastuzumab (2007) (0)
Use of disseminated tumor cells to predict outcome in patients with stage I-III breast cancer. (2012) (0)
Shorter-Course Breast Irradiation (2015) (0)
Assessment for residual nodal disease after neoadjuvant chemotherapy with image-guided surgery. (2014) (0)
Early Exercise After Breast Cancer Surgery Improves Outcomes (2021) (0)
Factors Associated with Skin Telangectasias and Cosmetic Outcome in Patients Treated on the American Society of Breast Surgeons MammoSite Registry Trial (2008) (0)
Axillary Dissection Unnecessary in Breast Cancer Patients with Positive Sentinel Lymph Nodes (2017) (0)
Abstract LB-240: Circulating tumor cell (CTC) analysis in NRG oncology/RTOG 1014, repeat breast conserving treatment after in-breast recurrence (IBR) (2017) (0)
Implementing value-based cancer care: A multidisciplinary approach to defining breast cancer outcomes. (2016) (0)
Effect of modest delays in primary surgical treatment on progression of tumor size in breast cancer patients. (2009) (0)
Patient interest in exploring nonsurgical treatment approaches for early-stage breast cancer: A qualitative study. (2022) (0)
Predictors o f L ocal-Regional R ecurrence A fter N eoadjuvant Chemotherapy a nd M astectomy W ithout R adiation (2002) (0)
Moving Forward with Omission of Breast Cancer Surgery Following Neoadjuvant Systemic Therapy (2022) (0)
Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy (2012) (0)
Micro-anatomical quantitative optical imaging: toward automated assessment of breast tissues (2015) (0)
For Managing Ductal Carcinoma in Situ, How Important Is Choice of Surgeon? (2011) (0)
Is PET Useful in Management of Colorectal Metastases (2014) (0)
Evaluation of the stage IB designation of the 7th edition of the AJCC Staging System. (2012) (0)
Perioperative Bevacizumab for Resection of Hepatic Colorectal Metastases (2007) (0)
P65 MammoSite Radiation Therapy System (RTS) as theSole Radiation Technique for DCIS of the Breast after Lumpectomy: A Phase II Trial (2005) (0)
Resection of Cavity Shave Margins in Breast Conserving Surgery (2019) (0)
Determining the optimal approach to breast reconstruction after partial mastectomy. Discussion (2006) (0)
Predictors of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ (DCIS) who underwent evaluation for BRCA genetic testing. (2012) (0)
Factors influencing treatment of inflammatory breast cancer in the United States. (2015) (0)
Predictors of systemic recurrence and impact of local failure among early stage breast cancer patients treated with breast conserving therapy (2001) (0)
Adjuvant Radiotherapy in Older Women with Early Breast Cancer: Benefits Questioned (2013) (0)
Predictors of Persistent Micrometastatic Disease after Neoadjuvant Chemotherapy. (2009) (0)
A multi‐institutional prediction model to estimate the risk of recurrence and mortality after mastectomy for T1‐2N1 breast cancer (2022) (0)
Sentinel Node Biopsy for Breast Cancer (2014) (0)
Sentinel Node Biopsy for Breast Cancer: An Update (2016) (0)
No Treatment Versus Partial Mastectomy Plus Radiation for Ductal Carcinoma In Situ (2021) (0)
Is the Rising Use of Bilateral Mastectomy for Unilateral Breast Cancer Advantageous (2014) (0)
Predicting Outcomes After Surgery for Colorectal Liver Metastases (2013) (0)
II mage-Detected Breast Cancer : State of the Art iagnosis and Treatment (2005) (0)
Should Breast Cancer Survivors with Lymphedema Avoid Strength Training (2009) (0)
Outcomes After Gastric Resection (2007) (0)
4–3 Ductal Lavage of Fluid-Yielding and Non–Fluid-Yielding Ducts in BRCA1 and BRCA2 Mutation Carriers and Other Women at High Inherited Breast Cancer Risk (2006) (0)
Preoperative Radiotherapy Trials to Facilitate Immediate Breast Reconstruction after Mastectomy (2019) (0)
Trends in Breast Reconstruction After Mastectomy (2014) (0)
Percutaneous ablation of breast tumors: Towards an era of surgery without scalpels (2002) (0)
Additional Cavity Shaving During Lumpectomy Reduces Positive Margin Rate (2015) (0)
Burnout Is Prevalent Among Medical Oncologists (2014) (0)
Abstract P4-15-02: Timing of infectious complications following breast conserving therapy with catheter-based accelerated partial breast irradiation (2012) (0)
Surgical techniques, biomaterials, and patient variables that impact peri-operative nipple necrosis in nipple-sparing mastectomy. (2012) (0)
Isolated Tumor Cells and Micrometastases in Breast Cancer (2009) (0)
Factors associated with lymphedema in patients/women with node positive breast cancer treated with neoadjuvant chemotherapy and axillary dissection on a prospective clinical trial. (2018) (0)
Long-term complications associated with breast-conservation surgery and radiotherapy. (2002) (0)
Reply to Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2‐positive breast cancer (2011) (0)
Regional Nodal Irradiation for Early-Stage Breast Cancer (2015) (0)
DCIS and sentinel lymph node biopsy (2015) (0)
Nipple-Sparing Mastectomy for Invasive Breast Cancer (2019) (0)
Predictors of cosmesis in women enrolled on the American Society Of Breast Surgeons MammoSite® Registry Trial (2008) (0)
Opioid prescriptions after breast cancer surgery: Perception and reality. (2018) (0)
Trastuzumab (Herceptin) for Ductal Carcinoma in Situ of the Breast (2006) (0)
2-25 The significance of surgical margins for patients with atypical ductal hyperplasia (2007) (0)
Treatment Trends for Early-Stage Breast Cancer (2014) (0)
Clinical Studies of Vaccines Targeting Breast Cancer 1 (2003) (0)
Impact on overall survival of primary tumor extirpation in breast cancer patients who present with stage IV disease (2007) (0)
Factors leading to the decision for contralateral prophylactic mastectomy in patients with breast cancer. (2009) (0)
Do HT Use and Hormone-Receptor Status Affect Recurrence After Treatment for Early-Stage Breast Cancer? (2007) (0)
P4-06-02: Microscopic Disease in Blood and Bone Marrow Predicts Survival in Early Stage Breast Cancer. (2011) (0)
A case study from M.D. Anderson Cancer Center: 26-year-old female with self-palpated axillary adenopathy (2005) (0)
1–43 Postlumpectomy Insertion of the MammoSite Brachytherapy Device Using the Scar Entry Technique: Initial Experience and Technical Considerations (2006) (0)
Hope for Patients with Gastric Cancer (2006) (0)
Lymphatic mapping for male breast cancer (2001) (0)
Genetic Testing for Breast Cancer: How Effective Are Guidelines? (2018) (0)
Mortality After Surgery for Hepatic Colorectal Metastases (2006) (0)
Outcomes and Predictive Factors for Salvage Therapy After Locoregional Recurrence Following Breast Conserving Therapy With Neoadjuvant Chemotherapy (2012) (0)
Effectiveness Without Efficacy: Cautionary Tale from a Landmark Breast Cancer Randomized Controlled Trial (2023) (0)
Should ductal carcinoma in situ be treated (2014) (0)
2-23 Salvage Treatment for Local or Local-Regional Recurrence After Initial Breast Conservation Treatment With Radiation for Ductal Carcinoma In Situ (2006) (0)
LOP09: Biomarkers in Breast Cancer as Preoperative Predictors of Adjuvant Radiation Treatment and Cancer Recurrence—The Dawn of Genomics in Plastic Surgery Practice (2014) (0)
Abstract 1368: Investigating the tumorigenicity of disseminated tumor cells (2012) (0)
Comprehensive Breast Care for the Future from the American Society of Breast Surgeons (2019) (0)
Abstract P5-13-03: Factors associated with prophylactic mastectomy among BRCA-positive patients with no personal history of breast cancer (2013) (0)
Integration of neoadjuvant systemic therapy into surgical practice (2010) (0)
Targeted biologic therapy in DCIS of the breast (2006) (0)
Dual-Modality Screening After Conservation Surgery for Breast Cancer (2017) (0)
Pathologists Do Not Agree on Breast Diagnoses 25% of the Time (2015) (0)
Effect of Preoperative Bevacizumab on Hepatic Cancer Surgical Outcomes (2008) (0)
I 1 State of the Science and the Intraductal Approach for Breast Cancer (2009) (0)
Radiotherapy for Ductal Carcinoma In Situ After Breast-Conserving Surgery (2014) (0)
Six-year Analysis of Treatment-related Toxicities by the American Society of Breast Surgeons MammoSi (2011) (0)
Baseline proliferation markers and cytopathologic findings in breast epithelium of women at increased risk for breast cancer (2005) (0)
Breast cancer metastasis through the lympho-vascular system (2018) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Henry Mark Kuerer?

Henry Mark Kuerer is affiliated with the following schools:

Université libre de Bruxelles
MD Anderson Cancer Center
University of Michigan
Baylor College of Medicine

Henry Mark Kuerer's Academic­Influence.com Rankings

Why Is Henry Mark Kuerer Influential?

Henry Mark Kuerer's Published Works

Published Works

What Schools Are Affiliated With Henry Mark Kuerer?

Henry Mark Kuerer's AcademicInfluence.com Rankings